Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cobimetinib
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: GH29914, NCI-2016-00260, 2015-003386-28, NCT02670044
Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
Anti-CSF1R Monoclonal Antibody IMC-CS, Vemurafenib, and Cobimetinib in Treating Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-030, NCI-2017-01198, NCT03101254
Cobimetinib in Treating Patients with Histiocytic Disorders
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-216, NCI-2016-00061, NCT02649972
Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and overt
Trial IDs: A071601, NCI-2017-00740, A071601
Atezolizumab with or without Cobimetinib in Treating Patients with Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10139, NCI-2017-01127, ETCTN10139, NCT03201458
Hsp90 Inhibitor XL888, Vemurafenib, and Cobimetinib in Treating Patients with BRAF Mutated Stage IIIB-IV Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18597, NCI-2016-01261, NCT02721459
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CO39083, NCI-2016-01406, 2016-000584-16, NCT02876224
Start Over